echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > China Resources Shuanghe Irbesartan Dispersible Tablets are the first to pass the quality and efficacy consistency evaluation of generic drugs

    China Resources Shuanghe Irbesartan Dispersible Tablets are the first to pass the quality and efficacy consistency evaluation of generic drugs

    • Last Update: 2021-07-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

           On June 5, China Resources Shuanghe issued an announcement that its wholly-owned subsidiary, Shuanghe Limin Irbesartan Dispersible Tablets, passed the approval of the Quality and Efficacy Consistency Evaluation of Generic Drugs by the State Food and Drug Administration on May 24, and obtained the "Supplementary Drug Application" Approval Notice" (Notice Number: 2021B01604), which is the first dispersible tablet approved

           The drug is mainly used for the treatment of essential hypertension and type 2 diabetic nephropathy combined with hypertension

           Irbesartan tablets, developed by the French company Sanofi, were approved by the European Medicines Agency (EMA) on August 27, 1997, and were approved by the U.
    Food and Drug Administration (FDA) on September 30, 1997.
    It was approved by the Japan Pharmaceuticals and Medical Devices Agency (PMDA) on April 16, 2008

    The trade names of Irbesartan tablets produced by Sanofi in Europe and the United States are APROVEL and AVAPRO, respectively


           The dosage form produced by Shuanghe Limin is irbesartan dispersible tablets
    According to data from Minai.
    com, the total sales of irbesartan oral preparations in 2020 will be 2.
    193 billion yuan

    Irbesartan oral preparations include ordinary tablets, dispersible tablets and capsules in China, including 11 ordinary tablets, 3 dispersible tablets, and 5 capsules

    Combining medical and urban retail data, Shuanghe Limin irbesartan dispersible tablets accounted for 3.
    60% of the domestic sales of irbesartan oral preparations, ranking sixth, of which the top five manufacturers are all ordinary tablets

    In 2020, Shuanghe Limin's drug sales revenue was 84.
    39 million yuan


           This review will benefit the future market sales of the drug and accumulate valuable experience for the follow-up evaluation of the consistency of generic drugs for other products, which will have a positive impact on the company's business performance

    If this article violates your rights, please contact us

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.